Abstract: Cosmetic compositions in the form of an oil-in-water emulsion include a) at least one monoglycerol fatty acid ester A, b) at least one first polyglycerol difatty acid ester B, c) at least one second polyglycerol difatty acid ester C which differs from the first polyglycerol difatty acid ester B, d) at least one fatty acid ester of the general formula (I) the residues R1 and R2 mutually independently denoting a saturated or unsaturated alkyl residue with 16 to 26 carbon atoms, and e) at least one skin-lightening active substance. A method includes using such compositions.

Abstract: The invention relates to a composition comprising at least i) one coupler of formula (I), and also addition salts thereof, optical or geometrical isomers thereof, tautomers thereof or solvates thereof: in which formula (I): X represents a halogen atom, a COOH group or an amido group —C(O)—NR5R6 with R5 and R6, which may be identical or different, representing a hydrogen atom or an alkyl group, R1 to R4, which may be identical or different, represent a hydrogen or halogen atom, an alkyl group or an alkoxy group, and ii) at least one oxidation base. The invention also relates to a process for dyeing keratin fibres using said composition.

Abstract: The present invention is relates to a novel anhydrous dermatological depigmenting compositions comprising a phenolic compound, and methods of making and using the same.

Abstract: The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analogue. In one embodiment, the prostaglandin analogue is latanoprost. In a preferred embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.

Abstract: Provided is a composition for an external use skin preparation, containing thioredoxin, and more specifically, to a composition which contains thioredoxin thereby providing an overall improvement in skin condition such as a remarkable improvement in skin moisturization, reduction in a transepidermal water loss, sebum control, pore contraction, an improvement in skin color through blood circulation improvement, and the like.

Abstract: A method for simultaneously moisturizing and/or blurring the appearance of skin defects, or reducing pore size, or treating skin with a multi-benefit composition.

Abstract: The present invention relates to a cosmetic agent for dyeing keratinic fibers, in particular human hair, including at least one quaternized copolymer of vinylpyrrolidone and dimethylaminoethyl methacrylate, and at least one oxidation dye precursor and/or a direct dye, wherein the use of the at least one quaternized copolymer of vinylpyrrolidone and dimethylaminoethyl methacrylate leads to improved conditioning, in particular to an increased volume, of the keratinic fibers with a simultaneously very low color shift.

Abstract: Disclosed herein in some embodiments are compositions and methods for treating or cosmetically addressing skin conditions. In certain embodiments, the compositions utilize optically transparent carriers and are capable of dissolving hydrophilic and hydrophobic active ingredients. In an embodiment, the compositions comprise a volatile silicone, an organic alcohol, and a diester. In another embodiment, the compositions comprise a volatile silicone, specially-denatured ethanol, and diisopropyl sebacate. In another embodiment, the volatile silicone comprises a mixture of octamethyltrisiloxane and dimethicone. In other embodiments, the compositions are used to treat skin conditions. Methods of treating or improving skin firmness, skin hydration, skin wrinkles and fine lines, and skin clarity, among other methods, are disclosed.

Abstract: An aerosol antiperspirant composition is provided. The aerosol antiperspirant composition includes a propellant and an antiperspirant composition. The antiperspirant composition includes one or more liquid materials, wherein the one or more liquid materials comprise one or more non-volatile silicone fluids having a concentration from 40% to about 70% by weight of the antiperspirant composition; antiperspirant active particulates having a concentration from about 16% to about 32% by weight of the antiperspirant composition; one or more non-antiperspirant active particulates that are substantially inert, wherein the one or more non-antiperspirant active particulates that are substantially inert have a concentration from 10% to 30% by weight of the antiperspirant composition; and wherein the antiperspirant composition has a total particulate concentration from 30% to about 60% by weight of the antiperspirant composition.

Abstract: An aerosol antiperspirant composition is provided. The aerosol antiperspirant composition includes a propellant having a concentration from 30% to 65% by weight and an antiperspirant composition. The antiperspirant composition includes one or more liquid materials, wherein the one or more liquid materials comprise one or more non-volatile silicone fluids having a concentration from 40% to about 70% by weight; antiperspirant active particulates; one or more non-antiperspirant active particulates that are substantially inert; and wherein the antiperspirant composition has a total particulate concentration from 30% to about 60% by weight and the antiperspirant composition has a viscosity greater than 1,000 centipoise.

Abstract: The present invention discloses a cosmetic composition intended for skin whitening, more particularly a whitening agent comprising the extract of Alpinia officinarum or the association between extracts of Physalis angulata, Bidens pilosa and Achyrocline satureioides included in a structured lipid network for delivery of bioactive compounds.

Abstract: Compositions and thin films containing an encapsulated active pharmaceutical ingredient, as well as methods of manufacturing and using the same.

Abstract: A bioadhesive strip includes material that is removable or dissolvable in the oral cavity and adheres to the mucosal tissue of a person's oral cavity, with preferred embodiments including a specially textured surface on at least the outer side of an adhesive strip that faces away from the mucosal tissue to which it is attached and that has anti-microbial characteristics, bioluminescent expressions, etc. and a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth. Methods of using the bioadhesive strip include treating snoring, sore throat conditions, GERD, NAFLD, Alzheimer's Disease, cachexia and migraines.

Abstract: A method and system for addressing the avoidance of migraines, cluster headaches and dizziness by adjusting an individual's microbiome, and in particular, to the provision of beneficial oral and gut microbes at particular times to enhance a person's oral health, including through the use of oral strips that adhere to surfaces in the oral cavity.

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Abstract: Disclosed are methods of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject a tumescent composition comprising: (a) the drug or the therapeutic agent, wherein a tumescent concentration of the drug is simultaneously: 1) below a threshold for local, subcutaneous tissue toxicity, 2) above a threshold for positive local therapeutic effect, and 3) above a concentration achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; (b) a vasoconstrictor; and (c) a pharmaceutically acceptable carrier. Some embodiments relate to a method of treating or preventing sepsis or Systemic Inflammatory Response Syndrome (SIRS) in a subject. Some embodiments relate to a tumescent solution for treating a localized viral infection, e.g., varicella-zoster (shingles), the tumescent solution comprising an antiviral agent.

Abstract: Disclosed herein is an article that includes a first plurality of spaced features. The spaced features are arranged in a plurality of groupings; the groupings of features include repeat units; the spaced features within a grouping are spaced apart at an average distance of about 1 nanometer to about 500 micrometers; each feature having a surface that is substantially parallel to a surface on a neighboring feature; each feature being separated from its neighboring feature; the groupings of features being arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20.

Abstract: The invention relates to a system for the sequential intranasal administration of at least one active ingredient selected from a DR group having at least one side effect of respiratory depression and at least one active ingredient selected from an ADR group that counteracts the respiratory depression that may be induced by the active ingredients of the DR group. The invention also relates to a portable sequential intranasal administration device comprising an intranasal administration system according to the principles of the invention.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same to treat a burn wound. In particular, nanoemulsion compositions are described herein that find use in reducing and/or preventing progression/conversion of a partial thickness burn wound (e.g., to deep partial thickness wound or a full thickness burn wound (e.g., by accelerating and/or improving burn wound healing)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

Abstract: The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers and perhalogenated fluorous compounds, such as perfluorooctyl bromide or perfluorodecalin, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth (e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients.

Abstract: The present invention relates to compositions and methods of stabilizing naltrexone hydrochloride.

Abstract: The method of treating diabetic wounds using biosynthesized nanoparticles includes administering an effective amount of silver and gold nanoparticles to a patient in need thereof. The silver and gold nanocomposite is prepared by ‘biosynthesis”, i.e., by providing a first aqueous solution of a noble metal salt or a noble metal oxide; providing a second solution of an aqueous plant extract, and combining the first solution and the second solution to produce a solution including nanoparticles of the noble metal. The second solution includes a plant extract obtained from Solenostemma argel, Trigonella foenum-graecum and Cinnamomum cassia. The metal salt can include silver nitrate (AgNO3) and chloroauric acid (HAuCl4). Nanoparticles of gold and nanoparticles of silver are prepared separately, and then mixed to obtain a composition containing a gold and silver nanocomposite.

Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention.

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.

Abstract: Disclosed are crosslinked particles (e.g., microparticles) that are capable of storing and releasing drugs. The particles can be macroparticles, microparticles, or nanoparticles and can be composed of polyester backbones. The particles can be loaded with a drug. The particles can degrade in vivo to release the drug. The particles can be prepared by crosslinking functionalized polyester backbones and loaded with a given drug. The particles of the present disclosure can be injected with a syringe. In some embodiments, the particles of the present disclosure are administered in connection with a surgery and release the drug after the site of the surgery for a period of 1-6 months.

Abstract: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.

Abstract: Methods for treating a wound are provided herein. Such methods include a step of contacting the wound with an effective amount of a BRAF inhibitor. In some aspects, BRAF inhibitors may be part of a pharmaceutical composition. In such case, the pharmaceutical composition may include an effective amount of a BRAF inhibitor and a pharmaceutically acceptable carrier. In certain aspects, the pharmaceutical composition is a topical agent comprising an ointment, cream liquid, gel, hydrogel, or a spray. Further, in some embodiments, a BRAF inhibitor or a pharmaceutical composition thereof may be part of wound dressing for use in treating a wound. In this case, the wound dressing may be impregnated or coated with the BRAF inhibitor or pharmaceutical composition thereof.

Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: The present invention discloses an invention comprising a treatment regime for chronic sinusitis. The regime includes destruction of biofilm and prevention of its formation achieved by a series of applications of compositions that comprise phenol, phenolic, or polyphenolic compounds as a contact/topical application to sinus membranes/tissue. The compositions may comprise phenolic or other compounds sourced naturally. Over-the-counter therapeutic use or in-office application or therapy are all possible implementations.

Abstract: Divalent salts of S-allylmercapto-N-acetylcysteine and related compositions are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compositions include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.

Abstract: The present invention relates to extended release compositions of an amino-C2-C6-alkyl nitrate and of pharmaceutically acceptable salt thereof, in particular 2-aminoethyl nitrate, and to fixed dose combinations with further pharmaceutically active drug substances. 2-Aminoethyl nitrate does not provoke nitrate tolerance, but has a very short half life in physiological systems.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.

Abstract: Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.

Abstract: The olfactory receptor Olfr78/OR51E2 is shown to be expressed in the carotid body and to control breathing responses regulated by acute hypoxia sensing. Activation of Olfr78/OR51E2 increases breathing, while inhibitors of the receptor can counteract this activity. A native agonist of Olfr78/OR51E2 is shown to be lactate.

Abstract: A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amount sufficient to produce a physiologically acceptable ketosis in the subject. A method for selecting a subject for treatment of a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) is also provided. Ketogenic compositions and kits useful for practicing the methods are also provided.

Abstract: A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.

Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Abstract: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care.

Abstract: Described is a method of inhibiting central apnea, central hypopnea or obstructive sleep apnea in a mammal. The method includes the step of administering to a mammal a central apnea inhibitory-effective, central hypopnea inhibitory-effective or obstructive sleep apnea inhibitory-effective amount of a composition comprising at least one retinoid or retinoid or retinoic acid receptor agonist.

Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: Gold(III) complexes having mixed ligands as anticancer agents. The gold(III) complexes are coordinated to bidentate ligands having diamino functional groups: a diaminocyclohexane ligand and an ethylenediamine ligand. These complexes can exist in both cis- and trans-configurations.